Disclosed herein is the use of DNA aptamer assemblies of varying DNA length, structure, and sequence to both bind to collagen and other proteins, to then act as a biocompatible, degradable, reversible, or permanent 3D crosslinkers between proteins, and to service as a biologically functional material when using the appropriate aptamer sequence. Therefore, disclosed herein are compositions comprising collagen fibers crosslinked with DNA aptamers. Also disclosed are devices and implants made from or coated with collagen fibers crosslinked with DNA aptamers. Also disclosed are methods of making collagen fibers. Also disclosed are kits for producing collagen fibers. Also disclosed herein are compositions DNA aptamers in a collagen fiber matrix that stabilizes the DNA aptamer.

A novel nucleic acid delivery system is provided containing a linear histidine-lysine rich cysteine-containing peptide bearing a targeting function, and a four branched histidine-lysine rich polypeptide. The delivery system includes a nucleic acid, such as an siRNA. The components form a nanoparticle complex through multiple non-covalent interactions between the phosphates of siRNA and histidine/lysine of the polypeptide, with reduced toxicity. The stable complex selectively delivers the genetic material to cells. The targeting function enhances the efficiency of the nucleic acid delivery and transfection.

Carrier molecules also are provided that have the ability to deliver a therapeutic molecule to a specific cell within a tissue in the body. The carrier molecule is modified with a targeting ligand capable of binding to specific receptors present or upregulated on the cell to be targeted. The therapeutic molecule is an siRNA, miRNA, or other oligonucleotide. The targeting moiety is a small molecule, peptide, or protein that shows an affinity for a receptor present on the cell to be targeted.

A method for detecting a plurality of target substances using a plurality of conjugates each including a binding substance and a label is provided. The binding substance has an activity to bind to one of the target substances and the label causes a detectable phenomenon. The method includes binding at least some of the plurality of conjugates with the plurality of target substances, removing a remainder of the plurality of conjugates that is not bound to the plurality of target substances, and detecting the label. A molecular weight of the binding substance is less than a molecular weight of an immunoglobulin.

A conjugate includes a binding substance having an activity to bind to a target substance and a label causing a detectable phenomenon. A molecular weight of the binding substance is less than a molecular weight of an immunoglobulin.

This invention relates generally to delivery of circular polyribonucleotides and compositions thereof.

The present invention relates to a single-stranded DNA aptamer that binds to glutathione to inhibit oxidation of the glutathione or stabilize the glutathione, characterized in that the single-stranded DNA aptamer has one or more stem-loop structures; a method for oxidation prevention and stabilization of glutathione using the aptamer; and application to various fields such as pharmaceuticals, cosmetics, and food, using the aptamer. The aptamer of the present invention can be applied to various fields, such as pharmaceuticals, cosmetics, and food, which require oxidation prevention and stabilization of glutathione.

There is provided an aptamer for dengue virus, optionally an aptamer for dengue virus NS1 protein. The aptamer comprising at least one unnatural base, wherein the unnatural base may be 7-(2thienyl)imidazo[4,5-b]pyridine (Ds), pyrrole2-carbaldehyde (Pa) or 2-nitro-4-propynylpyrrole (Px). The aptamers of the invention may be used to identify a dengue infection in a subject. Also provided are mixtures and kits comprising the aptamer.

The present invention relates to the field of neurological diseases, particularly to neurodegenerative diseases caused by dipeptide repeat toxicity. The invention provides genetic and chemical inhibitors of the protein kinase NEK6 to treat amyotrophic lateral sclerosis and frontotemporal dementia.

The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect broth DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.

The present invention relates to a DNA aptamer binding specifically to early secretory antigenic target 6 kDa (ESAT6), a biosensor for diagnosis of tuberculosis, comprising the same, and a method for providing information for diagnosis of tuberculosis. The present inventors found that not only does a DNA aptamer according to the present invention have specific binding potential to ESAT6 protein, but also the binding affinity is excellent. When used, the DNA aptamer of the present invention can be thus expected to exhibit greater stability than a conventional ELISA method using an antibody. Hence, the aptamer is expected to find useful applications in the development of compositions for tuberculosis diagnosis, biosensors for tuberculosis diagnosis, and information providing methods for tuberculosis diagnosis.